PRCT
PROCEPT BioRobotics Corporation
PRCT lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
PRCT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
PRCT's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
PRCT PE Valuation
PRCT has no meaningful PE right now: it lost money over the past year.
PRCT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect PRCT's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
PRCT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.03 | -$0.51 |
| Q2 2026 | -$1.95 | -$0.41 |
| Q1 2026 | -$1.83 | -$0.14 |
| Q4 2025 | -$1.72 | +$0.03 |
| Q3 2025 | -$1.52 | +$0.43 |
| Q2 2025 | -$1.54 | +$0.52 |
| Q1 2025 | -$1.69 | +$0.43 |
| Q4 2024 | -$1.75 | +$0.49 |
PRCT lost $2.03 per share over the past year, a bigger loss than the year before.
PRCT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $98.3M | +18% |
| Q2 2026 | $94.5M | +19% |
| Q1 2026 | $83.1M | +20% |
| Q4 2025 | $76.4M | +12% |
| Q3 2025 | $83.3M | +43% |
| Q2 2025 | $79.2M | +48% |
| Q1 2025 | $69.2M | +55% |
| Q4 2024 | $68.2M | +57% |
PRCT's revenue has grown year over year every quarter since early 2021: $98M last quarter, up 18% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -28% | 0 points |
| Q2 2026 | -29% | -1 points |
| Q1 2026 | -39% | +0.5 points |
| Q4 2025 | -41% | -12 points |
| Q3 2025 | -28% | +11 points |
| Q2 2025 | -28% | +22 points |
| Q1 2025 | -40% | +22 points |
| Q4 2024 | -29% | +39 points |
PRCT's operating margin was −28% last quarter, about level with the same quarter a year ago, near the top of its range since 2020.
PRCT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$9.7M | -$149K |
| Q2 2026 | -$22.2M | -$4.4M |
| Q1 2026 | -$41M | -$22.2M |
| Q4 2025 | -$12.2M | +$21.4M |
| Q3 2025 | -$9.5M | +$9.5M |
| Q2 2025 | -$17.8M | -$1.1M |
| Q1 2025 | -$18.8M | +$15.4M |
| Q4 2024 | -$33.6M | -$57K |
PRCT has burned cash in almost every quarter: −$85M over the past year, against −$80M the year before.
PRCT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +259K shares |
| 1 year | +2.9% | +1.6M shares |
| 3 years | +19% | +9M shares |
| 5 years | +39% | +16.1M shares |
PRCT has 57M diluted shares, up 2.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
PRCT Net Leverage
PRCT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
PRCT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.6 | Neutral |
| Stochastic | 60.7 | Neutral |
PRCT's weekly RSI is 55 (neutral) and its Stochastic is 61 (neutral).
PRCT PE vs Healthcare Sector
PRCT has no meaningful PE right now: it lost money over the past year.
PRCT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $19.2 | 22% above |
| 20 week MA | $19.9 | 18% above |
| 50 week MA | $24.5 | 3.8% below |
| 100 week MA | $39.0 | 40% below |
| 200 week MA | $44.3 | 47% below |
PRCT has bounced recently, but its long-term trend is still down: it's above its 8- and 20-week averages, but 47% below its 200-week average.
PRCT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $40.0 | $27.0 | -32% |
| 2022 | $27.0 | $40.9 | +51% |
| 2023 | $40.9 | $41.9 | +2.4% |
| 2024 | $41.9 | $82.0 | +96% |
| 2025 | $82.0 | $32.4 | -60% |
| 2026 YTD | $32.4 | $23.5 | -27% |
PRCT has finished higher in three of the last five years, two of them by more than 50%. It's down 27% so far in 2026.